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Objective To evaluate the incidence of febrile urinary tract infection (UTI) after successful endoscopic correction
of intermediate and high-grade vesicoureteral reflux (VUR).
Study design Medical records of 1271 consecutive children (male, 411; female, 903) who underwent successful
endoscopic correction of VURwere reviewed. Factors potentially influencing postoperative UTIs, such as history of
presentation, age, sex, grade of VUR, renal scarring, and agent used for the endoscopic injection, were analyzed.
Results Febrile UTI developed in 73 children (5.7%) after successful endoscopic correction of VUR. Thirty-nine
children had a single episode of UTI, and 34 children had two or more episodes at 1 month to 5.9 years (median,
1 year) after correction of VUR. With multivariate analysis, female sex (P < .001), history of preoperative bladder/
bowel dysfunction (BBD; P = .005), and BBD after endoscopic correction (P = .001) were revealed to be the
most important independent risk factors for a febrile UTI after successful correction of VUR.
Conclusions The incidence of febrile UTIs after successful correction of intermediate and high grade VUR is low.
Female sex and BBD were the most important risk factors in the development of febrile UTI. Our data supports the
importance of assessing bladder and bowel habits in older children with febrile UTIs after endoscopic correction of
VUR. (J Pediatr 2012;-:---).
V
esicoureteral reflux (VUR) is the most common urinary tract abnormality in pediatrics, occurring in 1% to 2% of chil-
dren, including 30% to 40% of children with urinary tract infection (UTI).1,2 The association of VUR, febrile UTI, and
renal parenchymal damage is well recognized. Reflux nephropathy is a cause of childhood hypertension and chronic re-
nal failure.3 Marra et al reviewed data on children with chronic renal failure who had high-grade VUR in the Italkid project,
a database of Italian children with chronic renal failure, and found that those with VUR accounted for 26% of all children with
chronic renal failure. The various treatment options currently available for VUR are: (1) long term antibiotic prophylaxis; (2)
open surgical treatment; (3) minimally invasive endoscopic treatment; and (4) observation or intermittent therapy with man-
agement of bladder/bowel dysfunction (BBD) and treatment of UTI as they occur.
Since United States Food and Drug administration approval in 2001 of dextranomer hyaluronic acid (Dx/HA) as a tissue
augmenting substance for subureteral injection, endoscopic treatment has become a widely accepted minimally invasive alter-
native in the management of VUR.
The main goals of treatment of children with VUR are to prevent renal parenchymal damage and morbidity associated with
recurrent febrile UTIs. Relatively few studies have examined the incidence of febrile UTIs after successful resolution of VUR
with endoscopic injection. The duration of follow-up in most series has been short, with conflicting rates of incidence of
UTI. Febrile UTIs after successful resolution of VUR have been reported at rates as low as 2.2% to as high as 27% of pa-
tients.4-9 The aim of this study was to determine the incidence of febrile UTIs in a large cohort of patients with intermediate
and high-grade VUR treated endoscopically.BBD Bladder/bowel dysfunctio
DMSA Dimercapto-succini acid
Dx/HA Dextranomer hyaluronic a
UTI Urinary tract infection
VCUG Voiding cysturethrograph
VUR Vesicoureteral refluxMethodsWe retrospectively reviewed the records of 1314 consecutive children with primary grade III to V VUR, who underwent success-
ful endoscopic correction of VUR between 1998 and 2007. Patients with VUR caused by neuropathic bladder, posterior urethral
valves, and ureteroceles were excluded from the study. Forty-three children (3.3%) were lost to follow-up after successful en-
doscopic correction. The remaining 1271 children comprised our study group and were included for analysis. Children with
grade II VUR were given endoscopic treatment only when grade II refluxing ureters were associated with high-grade VUR onFrom the National Children’s Research Centre, Our
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THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol.-, No.-the contralateral side. VURwas diagnosed in all children with
voiding cysturethrography (VCUG) and graded according to
the International Classification Systems (International Re-
flux Study Committee). Endoscopic treatment was com-
pleted on an outpatient basis according to a previously
described technique.10-12 The tissue augmenting substance
used for endoscopic injection was Teflon (polytetrafluoro-
ethylene, PTFE, Ethicon, Inc, Somerville, New Jersey) from
1998 to 2000. Since United States Food and Drug administra-
tion approval in 2001 of Dx/HA (Oceana Therapeutics, Inc,
Edison, New Jersey), Dx/HA has been used. Antibiotic pro-
phylaxis was continued after the endoscopic procedure, until
voiding cystourethrography and renal ultrasound scanning
were performed after 3 months. When voiding cystourethro-
gram showed resolution of reflux (grade 0-I), antibiotics
were stopped. A febrile UTI was diagnosed when results of
a urine culture showed a bacterial count >105 and grew a sin-
gle organism accompanied by a temperature$38.5C. In ad-
dition to fever, 8 patients also had dysuria and frequency. In
infants, the urine sample was collected with a urine bag. A
midstream urine sample was obtained and examined in older
children.
Factors potentially influencing postoperative UTIs, in-
cluding preoperative history of presentation (such as UTI,
prenatal hydronephrosis, sibling VUR, or BBD), sex, age,
agent used for the endoscopic injection, grade of VUR, renal
scarring on preoperative dimercapto-succini acid (DMSA)
scans and postoperative BBD, were analyzed. In addition,
the number of endoscopic treatments needed for resolution
of VUR was noted. Patients in whom febrile UTIs developed
after successful endoscopic correction of intermediate and
high grade VUR were classified as group I. Children in
whom febrile UTIs did not develop were classified as group
II. In patients in group I, the incidence of recurrence or neo-
contralateral VUR was evaluated. Detailed information was
obtained in patients with BBD. We considered children to
have BBD when their chart review revealed urgency, fre-
quency and/or daytime incontinence, infrequent voiding,
and constipation. BBD was treated with regular voiding,
timed voiding, complete bladder emptying, increased fluid
intake during daytime, and reduced fluid intake in the even-
ing. We also addressed bowel habits, such as the importance
of regular bowel movements, increased fiber intake, and lax-
atives when indicated before endoscopic injection.
Renal scarring was evaluated with DMSA scintigraphy and
classified in 3 groups: mild (focal defects in uptake between
40% and 45%), moderate (uptake of renal radionuclide be-
tween 20% and 40%), and severe (shrunken kidney with rel-
ative uptake <20%). DMSA scans were performed at least 4
to 6 months after an initial UTI.
As part of our standard policy, patients were observed 3
months after the endoscopic treatment with a routine
VCUG and renal ultrasound scan. Renal and bladder ultra-
sound scanning were performed again at 1 year and then ev-
ery 2 years thereafter for long-term follow-up, to monitor the
appearance of the upper urinary tract and the site and size of
the subureteral Dx/HA co-polymer implant.2Parents were instructed to report when their child devel-
oped a symptomatic UTI. They were asked to bring details
of treatment and urine culture reports when the children
were treated locally by general practitioners. A repeat
VCUG after successful endoscopic treatment was performed
when the children had two or more documented febrile UTIs
or showed pelvicalyceal dilatation on renal ultrasound scan-
ning after the first febrile UTI. We observed these children
from 3.5 years to 13.5 years (mean follow-up period, 7.6
years).
The c2 test and Mann Whitney U test were used for statis-
tical analysis of the data, and multiple logistic regression
analysis was used to identify independent variables for the
risk factors of febrile UTIs in children after successful endo-
scopic treatment of VUR, with a P value <.05 considered to
be statistically significant.
Results
Of the 1271 children, 863 were girls and 408 were boys, and
the median age at the time of endoscopic injection was 1.6
years (range, 2 month-13.3 years). The reflux was unilateral
in 637 patients and bilateral in 634 patients, comprising
1905 refluxing ureters. Grade of VUR at the time of endo-
scopic treatment was grade II in 76 refluxing units (4%),
grade III in 1047 refluxing units (55%), grade IV in 737 re-
fluxing units (39%), and grade V in 45 refluxing units
(2%). All children with grade II VUR had high-grade reflux
on the contralateral side. The indications for VCUG in the
1271 children were UTIs in 1135 (89.3%), screening for sib-
ling VUR in 80 (6.3%), urinary incontinence without a his-
tory of UTI but with pelvicalyceal dilatation on ultrasound
scanning in 51 (4%), and prenatally diagnosed hydronephro-
sis in 5 (0.4%). Children with BBD were 3.0 to 12.1 years old
(median, 10.2 years) at the time of injection therapy. Polyte-
trafluoroethylene was used for endoscopic injection in 253
patients and Dx/HA in the remaining 1018 patients.
Febrile UTI developed in 73 children (5.7%) after success-
ful endoscopic correction of intermediate and high-grade
primary VUR, and febrile UTIs did not develop in 1198 chil-
dren (94.3%). Details of the demographics of all patients are
summarized for the infection group and infection-free group
in Table I, which also gives information about descriptive
statistics for factors that may predict post-treatment UTI.
Twelve children (16.4%) with febrile UTIs after resolution
of VUR were hospitalized for intravenous antibiotic
therapy, and 61 children (83.6%) were treated with oral
antibiotics. UTI developed in the first year in 40 children
(55%), in the second or third year in 24 children (33%),
and 3 years after resolution of VUR in 9 children (12%).
Thirty-four children had two or more episodes of UTIs,
and 39 children had a single episode of UTI. Febrile UTIs
developed 1 month to 5.9 years (mean, 1 year) after
endoscopic correction of VUR. Escherichia coli were the
most common organisms (90%) isolated in urine cultures,
followed by Proteus mirabilis (7%) and Pseudomonas
aeruginosa (3%).Hunziker et al
Table I. Factors analyzed for assessing prediction of
febrile UTI after successful correction of VUR
Group 1
n = 73
(febrile UTI)
Group 2
n = 1198
(no febrile UTI)
P
value
Sex
Female 64 (7.4%) 799 (92.6%) <.001
Male 9 (2.2%) 399 (97.8%)
Presentation
UTI 59 (5.2%) 1076 (94.8%)
BBD 11 (21.6%) 40 (78.4%) <.001
Prenatal diagnosis 0 (0%) 5 (100%)
Screening for sibling VUR 3 (3.8%) 77 (96.2%)
Age in years
Median (range) 3.0 (0.2-9.5) 1.6 (0.1-13.3) .001
Agent for injection in n of patients
Teflon 24 (9.5%) 229 (90.5%) .004
Deflux 49 (4.8%) 969 (95.2%)
VUR laterality
Unilateral 33 604 .387
Bilateral 40 594
Grade of VUR
II 4 72
III 66 981 .805
IV 40 697
V 3 42
n of injections
1 injection 98 (6.0%) 1528 (94.0%)
2 injections 13 (5.3%) 231 (94.7%) .479
3 injections 2 (5.7%) 33 (94.3%)
BBD after endoscopic correction
Yes 23 (20.0%) 92 (80.0%) <.001
No 50 (4.3%) 1106 (95.7%)
All variables were compared with c2 test, except for age, for which Mann-Whitney U test was
used.
Table II. Renal scarring in children with or without
febrile UTI after endoscopic treatment of VUR
Renal scarring
Group I (febrile UTI)
n = 73
Group II (no febrile UTI)
n = 1057 P value
Mild scarring 14 134
Moderate scarring 11 105
Severe scarring 2 32
Total scarring 27 (37%) 271 (25.6%) .031
No scarring 46 (63%) 786 (74.4%)
- 2012 ORIGINAL ARTICLESFemale sex (P < .001), older age of patients (P = .001) and
Teflon as a tissue augmenting substance (P = .004) were
shown to contribute to a higher likelihood of febrile UTI after
successful endoscopic correction.
In the children in whom febrile UTI developed after endo-
scopic correction of VUR, the reflux at initial evaluation was
unilateral in 33 and bilateral in 40. The grade of VUR at di-
agnosis was grade II in 4 ureters, grade III in 66 ureters, grade
IV in 40 ureters, and grade V in 3 ureters. Only 43 of 113 ure-
ters (38%) had grade IV or V VUR. There was no significant
difference in the grade of VUR between the children in whom
UTI developed (group I) and the children without UTI
(group II) after correction of VUR.
Of the 73 children who had UTI after correction of VUR,
the reflux resolved in 98 refluxing units (86.7%) after one en-
doscopic injection. The reflux resolved after two injections in
13 refluxing units (11.5%) and after a third injection in two
refluxing units (1.8%). This is comparable with the outcome
of endoscopic treatment in children in whom UTI did not
develop after resolution of VUR.
All children in group I and 1057 of 1198 children in group
II had a DMSA scan to evaluate the renal parenchymal dam-
age. The incidence of renal scarring in group I with febrile
UTI after correction of VUR was 37%, compared with
25.6% in group II without UTIs (P = .031). Renal scarring
was also significantly higher in girls in group I, (n = 24,
37.5%) compared with girls in group II (n = 168, 24%;Incidence of Febrile Urinary Tract Infections in Children after Suc
Reflux: A Long-Term Follow-UpP = .027). Table II shows mild, moderate, and severe
scarring after endoscopic correction of VUR in group I and
group II.
All children in group I who had episodes of febrile
UTI underwent renal ultrasound scanning. At ultrasound
scanning, there was no evidence of delayed vesicoureteral
junction obstruction or significant changes in the size the in-
jected mound. However, in 3 patients, dilatation of the pelvi-
calyceal system was shown after the first febrile UTI. We
performed VCUG in all children who had two or more febrile
UTIs after endoscopic treatment or had pelvicalyceal dilata-
tion on ultrasound scanning after first febrile UTI. Thirty-
four children had two or more UTIs, and all these children
underwent VCUG. Three children showed prominence of
the pelvicalyceal system after first febrile UTI and also under-
went VCUG. Four patients had recurrence of VUR, and an-
other 3 patients had neocontralateral VUR on repeat VCUG.
In patients who had recurrence of VUR, the grade was grade
III in 3 ureters and grade IV in two ureters (unilateral -3,
bilateral -1). The grade of reflux in patients with neocontra-
lateral VUR was II in one patients and III in two patients. The
VURwas corrected after a single endoscopic injection in both
recurrent and neocontralateral VUR. Six of the 9 boys in
whom UTI developed after treatment were circumcised.
Occurrence of BBD before and after correction of VUR is
shown in Table I. Eleven patients (15.1%) in group I had
known BBD, and 40 patients (3.3%) in group II had BBD
before endoscopic treatment of VUR. BBD after endoscopic
correction was seen in 23 children (31.5%) in group I, with
10 of these children also having BBD before endoscopic
treatment. In group II, 92 children (7.7%) had BBD after
correction of VUR, with 17 of them also having BBD before
correction of VUR. Overall, BBD was cured in only one
patient in group I and 23 patients in group II after
endoscopic correction of VUR. In 13 of the 23 patients in
group I and 75 of the 92 patients in group II discovered to
have BBD after correction of VUR, BBD were considered to
be either newly diagnosed or misdiagnosed preoperatively
as not having voiding dysfunction.
Twenty-three children (31.5%), all girls, had a positive his-
tory of BBD after endoscopic correction of VUR diagnosed at
a median age of 6.5 years (range, 4.2-10.2 years). The inci-
dence of post-treatment voiding dysfunction was signifi-
cantly higher in patients in whom febrile UTIs developed
after endoscopic correction of VUR compared with patients
without UTIs (P < .001).cessful Endoscopic Treatment of Vesicoureteral 3
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a UTI (P = .018; OR, 2.1; 95% CI, 1.1-3.8) and BBD before
endoscopic treatment (P < .001; OR, 5.1; 95% CI, 2.5-10.5)
were shown to be significant risk factors for post-treatment
UTI.
Multivariate analysis revealed that female sex (P < .001,
OR, 3.8), polytetrafluoroethylene injection (P = .019, OR,
1.9), a history of preoperative BBD (P = .005; OR, 3.5), and
BBD after endoscopic correction (P = .001; OR, 2.9) were
the most important independent risk factors for a UTI after
successful endoscopic treatment of VUR (Table III). Renal
scarring and high-grade VUR were not significant factors.
Discussion
Endoscopic injection therapy has become a widely accepted
treatment for VUR. Parental preference plays a major role in
the selection of endoscopic treatment compared with long-
term antibiotic treatment or open surgical treatment. The en-
doscopic treatment is safe and effective and performed as an
outpatient procedure. However, ureteral re-implantation, ei-
ther extravesical or intravesical, involves an incision on the
lower abdomen and usually requires urethral catherization
and hospitalization. The outcome of endoscopic treatment
depends on the experience of the surgeon, and in experienced
hands, it is comparable with that of open surgical treat-
ment.10-12
Relatively few studies have examined the incidence of fe-
brile UTIs after successful treatment of VUR, either with
open ureteral reimplantation or endoscopic injection. In
the final report of International Reflux Study in children, Jo-
dal et al reported a 13% (17 of 125) incidence of febrile UTIs
after open surgical treatment in a 10-year period.13 Elmore
et al reported an incidence of febrile UTIs in 24% of children
after reimplantation of ureters.6
In their meta-analysis study of reflux resolution and UTI
after endoscopic treatment of VUR, Elder et al reported
a 6% incidence of UTI and only 0.75% incidence of pyelone-
phritis.14 Similarly Lackgren et al reported after a mean
follow-up of 5 years (range, 2-7.5 years) an 8% (19 of 228)
incidence of UTI and a 3.5% (8 of 228) incidence of pyelone-
phritis after successful endoscopic treatment (Table IV).7
Chi et al noted 24% incidence of symptomatic UTI, one-
half of these were febrile (12%) after reflux resolution with
Dx/HA injection in a median follow-up of 2.6 years.8 In
their study of 40 children who had successful endoscopicTable III. Multivariate analysis of risk factors predicting
febrile UTI after endoscopic injection
P value OR (95% CI)
Female sex <.001 3.8 (1.8-7.9)
Polytetrafluoroethylene injection .019 1.9 (1.1-3.3)
Grade IV, V VUR .931 1.0 (0.6-1.7)
Preoperative BBD .005 3.5 (1.4-8.3)
Renal scarring on preoperative DMSA scan .085 1.6 (0.9-2.7)
BBD after endoscopic treatment .001 2.9 (1.5-5.5)
4Dx/HA injection, Elmore et al reported an incidence of 5%
febrile UTIs after correction of VUR with endoscopic
treatment.6 Sedberry-Ross et al reported an incidence of
27% of febrile UTI after endoscopic treatment in their
series of 45 patients after a median follow-up of 2.9 years
and 2.5 years for the infection-free group and the infection
group, respectively.9 Traxel et al reported an incidence of
febrile UTIs of 3.5% after a mean follow-up of 2.6 years.5
The study performed by Chertin et al reported that the
incidence of febrile UTI after a median follow-up of 13
years (range, 1-20 years) was 2.2%.4 In most of these
studies, the follow-up period is short, from 2.6 years to 5
years, except for the study performed by Chertin et al. In
our large series of patients, followed for a period of 3.5 to
13.5 years (median, 7.6 years), the incidence of febrile UTIs
was 5.7%. In children with post-treatment febrile UTI who
underwent a repeat VCUG, the incidence of recurrent VUR
is reported to be between 35%8 and 82%.9 Repeat VCUG
also showed neocontralateral VUR in as many as 9%9 of
patients. In our study, the occurrence of recurrent or
neocontralateral VUR was low and noted in 19% of the
children with post-treatment febrile UTI who underwent
repeat VCUG.
E coli was the most common causative organism in 90% of
children who had UTI after resolution of VUR in our study.
This finding is similar to that of Wadie et al, who found an
E coli UTI in 82% of a post-injection group.15 In our study,
febrile UTI developed in most children (55%) in their first
year, after resolution of VUR. In their series, Elmore et al
have reported that UTI developed within the first year after
successful treatment in 83% of children in the Dx/HA group
and 86% in the open surgery group.6
One of the main goals of treating the child with VUR is
prevention of recurring febrile UTIs. Several large, prospec-
tive, randomized controlled trials have shown little to no
benefit of medical therapy for reducing the incidence of fe-
brile UTI or renal scarring.16 Surgical resolution of VUR gen-
erally reduces the risk of febrile UTIs. Therefore, in the recent
updated American Urological Association Guidelines on
Management of Primary VUR, surgical intervention for
VUR, including both open and endoscopic methods, were in-
cluded as a management option.16
Recently, the Swedish Reflux Trial in Children recruited
children between 1 and 2 years old with grade III to IV
VUR for a prospective, open, randomized controlled multi-
center study. Children were treated in 3 groups, including
low-dose antibiotic prophylaxis, endoscopic therapy, and
a surveillance group on antibiotics only for febrile UTI. After
2 years, endoscopic treatment results were significantly better
than the spontaneous resolution rate or downgrading in the
prophylaxis and surveillance groups.17 Furthermore, they
noted a high rate of recurrent febrile UTI in girls older
than 1 year, but not in boys. Although they found that 23%
of the girls in the endoscopic group had postoperative febrile
recurrent UTI, recurrent postoperative UTIs were signifi-
cantly decreased compared with those in control subjects in
the surveillance group.18Hunziker et al
Table IV. Incidence of febrile UTIs, follow-up, and injectables in other series
References Patients, n Injectables Mean/median follow-up, years (range) Febrile UTI %
Elder et al14 5527 51% polytetrafluoroethylene
21% collagen
10% Dx/HA
8% polydimethylsiloxane
2% chondrocytes
2% blood
8% 2 or more injectables
Not mentioned 0.75%
Lackgren et al7 228 Dx/HA Mean, 5 (2-7.5) 3.5%
Sternberg et al25 179 Dx/HA (6-11) 3.4%
Chi et al8 167 Dx/HA Median, 2.6 (0.6-4.4) 12%
Elmore et al6 40 Dx/HA Mean, 3.6 (3.2-3.9) 5%
Sedberry-Ross et al9 45 Dx/HA Median, 2.5 27%
Chertin et al4 507 Polytetrafluoroethylene: 369 pts
Dx/HA: 138 pts
Median, 13 (1-20) 2.2%
Traxel et al5 311 Dx/HA Mean, 2.6 (0.3-5.4) 3.5%
Brandstrom et al18* 66 Dx/HA Median, 2.05 21%
Current series 1271 Polytetrafluoroethylene: 253 pts
Dx/HA: 1018 pts
Median, 7.6 (3.5-13.5) 5.7%
*Prospective, randomized controlled study.
- 2012 ORIGINAL ARTICLESDysfunctional voiding syndrome and BBD refer to abnor-
malities of storage and emptying, often including constipa-
tion.16 The bladder part of this syndrome can be
recognized as dysfunctional voiding.19 Several studies have
shown risk factors for UTI after correction of VUR. It has
been reported that female sex and bilateral VUR are risk fac-
tors for post-treatment UTI.15 Sedberry-Ross et al stated that
9 of 12 children (75%) in the infection group had a history of
dysfunctional elimination, and 9 of 12 children (75%) had
multiple preoperative febrile UTIs.9 The incidence of renal
scarring was not statistically significant between the UTI
and the no UTI group. However, they stated that there was
a high number of renal scars in the entire cohort group.
Lackgren et al reported that 50% of children with postoper-
ative UTI had dysfunctional voiding.7 Chi et al showed that
girls, children with recurrent preoperative UTIs, older chil-
dren, and children with voiding dysfunction were more likely
to have a UTI after endoscopic treatment.8 They also per-
formed univariate analysis and found that the number of pre-
operative UTIs and dysfunctional voiding were significant
predictors of post-injection UTI. With their multivariate
analysis, however, only recurrent preoperative UTI was
found to be an independent risk factor. Traxel et al found
with multivariate analysis that recurrent UTI and bladder
dysfunction were independent predictors for postoperative
UTI.5 Female sex and preoperative renal scarring were not
significant. In the recently updated American Urological
Association guidelines, the rate of UTI after open or endo-
scopic surgery was greater in children with BBD (22%)
than children without BBD (5%).16
It is believed that endoscopic treatment of VUR in children
with dysfunctional voiding has an unfavourable outcome.20
This has been attributed to the displacement of the Dx/HA
implant in children with voiding dysfunction because high
intravesical pressure caused by uninhibited detrusor contrac-
tions may cause displacement of the Dx/HA implant. Cap-
pozza et al found a displaced implant in 27 children at
re-treatment after initial treatment failure, and of these 27Incidence of Febrile Urinary Tract Infections in Children after Suc
Reflux: A Long-Term Follow-Upchildren, 25 had dysfunctional voiding.20 Since we started
treating VUR endoscopically, we have not considered BBD
as a contraindication to endoscopic treatment. We only treat
dysfunctional voiding when it persists after successful correc-
tion of VUR. In our series, 23 of the 73 children (31.5%),
predominantly girls with febrile UTIs, had a positive history
of BBD after correction of VUR, whereas only 92 of the 1198
children (7.6%) who had no UTIs after endoscopic correc-
tion of VUR had history of BBD. In a study of 107 girls
with reflux, it was revealed that approximately 50% had void-
ing dysfunction, and they were 4 times more likely to experi-
ence breakthrough UTIs.21 The low incidence of BBD in our
patients after successful correction of VUR with endoscopic
treatment suggests that VUR may be contributory to dys-
functional voiding and resolution of VUR may improve dys-
functional voiding. Correction of VUR in our series cured
dysfunctional voiding in 74% of children. Similar, Lackgren
et al reported that injection of Deflux cured VUR in 45 pa-
tients (83%).22 Residual urine and incomplete bladder emp-
tying play an important role in the origin of infections. It has
been reported that voiding dysfunction is common in girls
with infections. As many as 66% of girls with voiding dys-
function have UTIs.23 In a retrospective study of medically
treated children with vesicouerteral reflux, the incidence of
breakthrough infection was increased in children with ur-
gency and incontinence.24 It is believed that VUR correction
decreases the risk of febrile UTI and thus prevents renal
parenchymal damage. Risk factors that may predict febrile
UTIs after correction of VUR need to be addressed. Patients,
especially girls, and children with BBD before and after cor-
rection of VUR require special attention.
An important limitation of this study is that we did not
perform VCUG in all children with febrile UTI after resolu-
tion of VUR. Children who had two or more febrile UTIs and
children who showed prominence of renal collecting system
on ultrasound scanning after the first febrile UTI underwent
VCUG. It therefore is possible that we may have missed low-
grade VUR in some patients. It is a retrospective study, and itcessful Endoscopic Treatment of Vesicoureteral 5
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rence of febrile UTI after resolution of VUR or minor BBD.
Furthermore, the DMSA scan was performed in 1130 of
1271 patients (89%) andmay havemissedmild renal scarring
in some patients.
Although one could argue that children with BBD could
have been biased by their young age, children with BBD in
our study were 3.0 to 12.1 years (median, 10.2 years) at the
time of injections. Furthermore, children who have BBD after
endoscopic injection received a diagnosis at a median age of
6.5 years. n
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